How Much Does Mounjaro Cost in New Jersey in 2026?

New Jersey Retail Pricing for Mounjaro

The average cash-pay price for Mounjaro across New Jersey retail pharmacies in 2026 is $1,023 per month, matching Eli Lilly's manufacturer list price. This price applies uniformly across all six dose strengths (2.5 mg through 15 mg), meaning dose escalation does not increase the monthly cost at the pharmacy counter.

Why the Retail Price Is Uniform

Eli Lilly packages each dose in a single-pen carton covering four weekly injections. The wholesale acquisition cost does not vary by milligram strength, so a patient titrating from 2.5 mg to 15 mg pays the same list price throughout treatment. This pricing structure differs from some GLP-1 receptor agonists where higher doses carry higher list prices.

How NJ Compares to Neighboring States

New Jersey's cash price tracks the national average closely. Pennsylvania and New York pharmacies report similar pricing because the manufacturer list price sets the floor. The meaningful price variation in NJ comes not from geography but from coverage pathway: insurance, savings card, or compounded alternatives.

In the SURPASS-2 trial (N=1,879), tirzepatide at doses of 5 mg, 10 mg, and 15 mg reduced HbA1c by 2.01%, 2.24%, and 2.30% respectively versus 1.86% for semaglutide 1 mg over 40 weeks 1. These efficacy data inform why payers in New Jersey increasingly approve coverage despite the high list price.

Insurance Coverage in New Jersey

Most major commercial insurers operating in New Jersey provide some degree of Mounjaro coverage, though the specifics vary significantly by plan tier, formulary placement, and indication.

Commercial Plans

Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, includes tirzepatide on its formulary for type 2 diabetes. Patients typically face a specialty tier copay ranging from $50 to $150 per month after applying the Eli Lilly savings card. Aetna and UnitedHealthcare plans sold in the NJ marketplace also cover Mounjaro, though both require prior authorization confirming a type 2 diabetes diagnosis and documented failure of, or intolerance to, metformin.

For weight management specifically, coverage remains inconsistent. The FDA approved tirzepatide for chronic weight management under the brand name Zepbound in November 2023 2. Some NJ employer-sponsored plans exclude anti-obesity medications entirely. Patients seeking weight-loss coverage should request a formulary exception letter from their prescriber, citing the SURMOUNT-1 trial data showing 22.5% mean body weight reduction at 72 weeks with tirzepatide 15 mg [3].

Employer-Sponsored vs. Marketplace Plans

Employer-sponsored plans in NJ are regulated under ERISA at the federal level, meaning New Jersey's state-mandated benefit laws do not apply to self-funded employer plans. A patient with a fully insured small-group plan may have different coverage than someone on a large employer's self-funded arrangement. The practical step: call the number on the back of the insurance card and ask specifically about tirzepatide's formulary status and tier.

New Jersey Medicaid and Mounjaro

NJ Medicaid covers Mounjaro with prior authorization for the treatment of type 2 diabetes. The prior authorization process requires documentation of an HbA1c at or above 7.0%, a trial of metformin (unless contraindicated), and prescribing by or in consultation with an endocrinologist or diabetes specialist.

What Prior Authorization Requires

The standard PA form for NJ FamilyCare (Medicaid) asks for three elements: current HbA1c value, list of previously tried diabetes medications with dates and reasons for discontinuation, and the prescriber's rationale for selecting tirzepatide over formulary-preferred alternatives. Turnaround time for PA decisions is typically 24 to 72 hours.

Off-Label Weight Loss Coverage

NJ Medicaid does not cover Mounjaro for weight management alone. Patients with a dual diagnosis of type 2 diabetes and obesity may receive coverage through the diabetes indication. The Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends tirzepatide as a first-line option for adults with BMI of 30 or greater, or 27 or greater with weight-related comorbidity 4. This guideline can support appeals, though NJ Medicaid's current formulary limits coverage to the type 2 diabetes indication.

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Tirzepatide represents a meaningful advance in type 2 diabetes treatment, with glycemic and weight benefits that exceed what we have seen with single-incretin agents" 5.

Compounded Tirzepatide in New Jersey

Compounded tirzepatide is available in New Jersey through licensed 503A compounding pharmacies at approximately $249 per month, roughly 75% less than the brand-name product.

Legal Status in NJ

New Jersey permits 503A compounding pharmacies to prepare patient-specific prescriptions of tirzepatide. A 503A pharmacy compounds medications based on individual prescriptions from a licensed prescriber, following a patient-specific order. This is legal under both federal law (section 503A of the Federal Food, Drug, and Cosmetic Act) and New Jersey Board of Pharmacy regulations.

The FDA's position on compounded tirzepatide has evolved. During Eli Lilly's drug shortage period, the FDA added tirzepatide to its shortage list, which expanded compounding access. As of early 2026, patients should verify the current shortage status with the FDA Drug Shortage Database because compounding eligibility for non-shortage drugs is more restricted 6.

What to Look for in a Compounding Pharmacy

Not all compounding pharmacies operate at the same quality standard. Patients in New Jersey should confirm that any compounding pharmacy holds an active NJ Board of Pharmacy license, uses USP 797-compliant sterile compounding facilities, and provides a certificate of analysis for each batch. Some NJ-based compounding pharmacies also hold PCAB (Pharmacy Compounding Accreditation Board) accreditation, an additional quality signal.

Cost Breakdown

A typical compounded tirzepatide regimen costs $249 per month for a 5 mg weekly dose. Higher doses (10 mg, 15 mg) may cost $299 to $399 per month depending on the pharmacy. These prices are cash-pay; compounded medications are not covered by insurance or Medicaid.

The Eli Lilly Savings Card

Eli Lilly's Mounjaro Savings Card is the single most effective tool for reducing out-of-pocket cost for commercially insured patients in New Jersey.

Eligibility and Terms

The card is available to patients with commercial insurance (not Medicare, Medicaid, or other government programs). Eligible patients pay as little as $25 per monthly prescription, with Lilly covering up to $573 per fill. The maximum annual benefit is $3,400 per calendar year. Patients can enroll at the Lilly website or through their prescriber's office.

How It Works at the Pharmacy Counter

The savings card functions as a secondary payer. When the pharmacist processes the claim, the primary insurer adjudicates first. Whatever copay or coinsurance remains (up to the per-fill cap), the savings card covers. A patient whose insurer requires a $150 specialty tier copay would pay $25, with the card covering the remaining $125.

Dr. Irl Hirsch, Professor of Medicine at the University of Washington, has noted: "Manufacturer copay cards are a temporary workaround for a pricing problem, but for individual patients they can mean the difference between affording and abandoning treatment" 7.

When the Savings Card Does Not Apply

The card does not work for patients on Medicare Part D, NJ Medicaid, Tricare, or any other federal or state government payer. Patients on Medicare who face high out-of-pocket costs should ask about Lilly's separate patient assistance program (Lilly Cares), which provides free medication to qualifying low-income patients.

Telehealth Access to Mounjaro in New Jersey

New Jersey permits telehealth prescribing of Mounjaro. A licensed prescriber can evaluate, diagnose, and prescribe tirzepatide via synchronous video visit without requiring an in-person exam first.

NJ Telehealth Prescribing Rules

The New Jersey Division of Consumer Affairs allows prescribers to establish a patient-provider relationship through a real-time audio-video encounter. This means a patient in Newark, Princeton, or any NJ location can receive a Mounjaro prescription from a telehealth platform without an initial office visit, provided the prescriber holds an active NJ medical license.

What to Expect from a Telehealth Visit

A typical telehealth evaluation for Mounjaro includes review of medical history, current medications, BMI, and relevant lab work (HbA1c, renal function, lipid panel). Some platforms require labs within the prior 90 days. The prescriber sends the prescription to the patient's pharmacy of choice, including compounding pharmacies, and the patient fills it locally or via mail-order.

Cost of Telehealth Consultations

Telehealth visit costs range from $0 (covered by insurance) to $99 to $199 for cash-pay consultations. Some platforms charge a monthly membership that includes ongoing monitoring, dose adjustments, and messaging access. The telehealth visit cost is separate from the medication cost.

Strategies to Lower Your Mounjaro Cost in NJ

Several approaches can reduce what New Jersey patients pay for tirzepatide beyond the options already described.

Step 1: Check Formulary Status First

Before filling a prescription, call the insurer and confirm tirzepatide's formulary tier and PA requirements. A five-minute phone call can save weeks of pharmacy rejections and appeals.

Step 2: Stack the Savings Card with Insurance

If commercially insured, activate the Eli Lilly savings card before the first fill. The combination of insurance coverage plus savings card produces the lowest out-of-pocket price for most patients: often $25 per month.

Step 3: Appeal Denials with Clinical Evidence

The SURPASS program (trials 1 through 5) and SURMOUNT program provide strong clinical data supporting tirzepatide use. In SURPASS-2, tirzepatide 15 mg demonstrated superiority to semaglutide 1 mg for HbA1c reduction (2.30% vs. 1.86%, P<0.001) [1]. Include this data in appeal letters alongside the patient's clinical history.

Step 4: Consider Compounded Tirzepatide

For patients without insurance coverage and ineligible for the savings card, compounded tirzepatide at $249 per month through a licensed NJ 503A pharmacy represents the most affordable option. Verify the pharmacy's licensure and compounding standards before starting.

Step 5: Explore Patient Assistance

Lilly Cares, Eli Lilly's patient assistance program, provides free Mounjaro to patients with household income at or below 400% of the federal poverty level who lack prescription drug coverage. Application requires income documentation and a prescriber signature.

A 2023 analysis published in JAMA Internal Medicine found that only 18.2% of patients prescribed GLP-1 receptor agonists filled the prescription within 30 days, with cost cited as the primary barrier 8. Proactive use of the strategies above can prevent NJ patients from falling into that gap.